By: IPP Bureau
Last updated : May 08, 2026 11:53 am
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
Biocon Limited reported FY26 operating revenue of Rs. 16,927 crore, up 13% year-on-year excluding one-time generic lenalidomide sales, while EBITDA rose 25% to Rs. 3,798 crore, led by strong growth in the biosimilars business and improved operational efficiency.
For Q4FY26, the company posted consolidated operating revenue of Rs. 4,517 crore, marking a 10% year-on-year increase after adjusting for one-time generic lenalidomide sales recorded in Q4FY25.
Total income for the quarter stood at Rs. 4,569 crore, while EBITDA rose 29% year-on-year to Rs. 1,073 crore, with EBITDA margins improving to 23%.
Net profit before exceptional items increased 64% year-on-year to Rs. 179 crore. The company invested Rs. 277 crore in research and development during the quarter, representing 8% of revenue excluding Syngene International Limited.
For the full financial year FY26, Biocon’s operating revenue rose 13% year-on-year to Rs. 16,927 crore after adjusting for one-time generic lenalidomide sales in FY25. Total income stood at Rs. 17,270 crore.
Annual EBITDA increased 25% to Rs. 3,798 crore after adjusting for one-time impacts and the BFI divestment gain in the previous fiscal. EBITDA margins improved by around 200 basis points to 22% on a like-to-like basis.
Net profit before exceptional items surged 323% year-on-year to Rs. 436 crore. R&D investments for the year stood at Rs. 982 crore, accounting for 8% of revenue excluding Syngene.
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year, supported by strong performance in advanced markets and key tender wins in emerging markets. The generics segment reported revenue of Rs. 3,168 crore, up 17% excluding one-time lenalidomide sales, while Syngene’s research services business grew 3% to Rs. 3,739 crore.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited commented, “Biocon closed FY26 on a strong note despite a complex geopolitical environment. We delivered margin expansion along with 13% YoY growth in operating revenue, excluding the one-time impact of generic lenalidomide sales last year. This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration.”
Shreehas Tambe, CEO & Managing Director, Biocon Limited said, “FY26 was a pivotal year for Biocon, marked by the successful integration of our biosimilars and generics business to create one unified biopharmaceutical enterprise with greater scale, capability, and reach. Even as we integrated the businesses, Biocon delivered ~200 basis points of EBITDA margin expansion at a consolidated level on a like-to-like basis, driven by an improved product mix and operational excellence.”
Peter Bains, CEO & Managing Director, Syngene International Limited said, “Our biosimilars business recorded 16% YoY growth in revenue and 40% increase in EBITDA, on a like-to-like basis. Growth was led by strong performance in advanced markets and key tender wins across emerging markets. With the integration now complete, we shift gears in fiscal 2027 from the “Preserve” phase of our strategy to “Consolidate”, as we set up the business for sustainable growth.”